Optimizing Treatment Strategies for Carbapenem-Resistant Acinetobacter Baumannii-Associated Pneumonia: A Multicenter Study in Chinese Hospitals
Xiaotong Tian,Jing Lin,Menglan Zhou,Ying Ge,Taisheng Li,Li Zhang,Zhengyin Liu
DOI: https://doi.org/10.2147/idr.s473088
2024-10-13
Infection and Drug Resistance
Abstract:Xiaotong Tian, 1, 2 Jing Lin, 1, 2 Menglan Zhou, 3, 4 Ying Ge, 1 Taisheng Li, 1 Li Zhang, 1 Zhengyin Liu 1 1 Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China; 2 Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China; 3 Department of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China; 4 Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases, Beijing, People's Republic of China Correspondence: Zhengyin Liu; Li Zhang, Department of Infectious Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China, Email ; Purpose: To evaluate the clinical outcomes and safety of tigecycline (TGC) plus cefoperazone/sulbactam (CPS) or TGC monotherapy in patients with hospital-acquired pneumonia (HAP) caused by Carbapenem-Resistant Acinetobacter baumannii (CRAB). Methods: This was a retrospective analysis of multicenter data from 62 Chinese hospitals with CRAB HAP. Risk factors for receiving TGC with CPS therapy and predictors of mortality were assessed using multivariate logistic and Cox regression analyses, respectively. Propensity score matching (PSM) evaluated the efficacy and safety of antimicrobial regimens. Results: A total of the 180 patients were included, with 95 receiving TGC monotherapy and 85 receiving combination therapy. Multivariate logistic regression analysis revealed that older age ( P = 0.011), and intensive care unit (ICU) admission ( P = 0.007) were significant risk factors for combination therapy. Multivariate Cox regression demonstrated that combination therapy was associated with a significantly higher risk of 90-day mortality ( P = 0.031). Patients in the standard-dose TGC (SDT) plus CPS subgroup had significantly higher rates of SOFA scores ≥ 7 ( P = 0.009) and MV used ( P = 0.028), as well as higher 30-/90-day mortality compared to high-dose TGC (HDT) plus CPS group. TGC plus CPS significantly reduced CRP levels ( P = 0.009), while the variations in ALT, TBIL, Cr, Hb, and PLT levels did not differ between different antimicrobial regimens after PSM. Conclusion: HDT and CPS combination therapy was more effective in patients with advanced age and more severe condition. Safety profiles of different antimicrobial regimens were similar with liver, kidneys, and coagulation functions. Keywords: carbapenem-resistant Acinetobacter baumannii , hospital acquired pneumonia, tigecycline, cefoperazone/sulbactam, risk factors The gram-negative bacilli (GNB) 1 were the primary pathogens of HAP in our country, with AB 2 being the most common, accounting for 25.6%. The treatment of AB is limited by the availability of antimicrobial agents due to its increasing resistance to various antibiotics, particularly carbapenems. Additionally, AB can survive long-term in vitro, making it widespread in the hospital environments. Patients with AB infections tend to have severe conditions, leading to longer lengths of hospital stay (LOS), higher medical costs, and worse prognosis. 3 In this circumstance, AB has been classified by the World Health Organization (WHO) as a priority on the global priority list for research and development of new antibiotics. 4 AB infections have thus become a major global public health issue, posing significant challenges to the safety of medical and healthcare systems worldwide. Strengthening surveillance and control efforts to prevent the spread of AB is crucial. In 2020, Chen et al 5 conducted a study on the in vitro activity of various antimicrobials against AB in the Asia-Pacific region, including novel β-lactam combination agents, TGC, and colistin. The study revealed that drug-resistant AB strains in China exceeded 70.0%, ranking third after South Korea and India. According to the China Antimicrobial Surveillance Network (CHINET) in 2021, 6 the rate of CRAB among clinical isolates had risen to 71.5%. While CRAB shows greater than 88.0% susceptibility to polymyxin B and tigecycline, 7 currently considered last resource antibiotics, the optimal treatment for CRAB infection remains controversial. For severe CRAB infections, TGC monotherapy may result in -Abstract Truncated-
pharmacology & pharmacy,infectious diseases